CAR T-cell therapy improves survival in relapsed or refractory lymphoma

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet. Marginal zone lymphoma (MZL) is a group of rare…

Continue Reading

News Source: medicalxpress.com